Immune cells engineered to fight virus-linked cancer show promise in early trial
NCT ID NCT04509726
First seen Jan 21, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This early-phase trial tested a new treatment for people with advanced nasopharyngeal cancer that is linked to the Epstein-Barr virus. The treatment uses specially engineered immune cells (TCR-T cells) that can recognize and attack the virus on cancer cells, plus they release a cytokine to boost the immune response. Nine participants received different doses to find the safest amount. The goal was to see if this approach is safe and tolerable, not yet to prove it cures the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.